Watson's Generic Lybrel Receives FDA Approval

Watson Pharmaceuticals, Inc. WPI today announced that its subsidiary, Watson Laboratories has received approval from the United States Food and Drug Administration for Levonorgestrel and Ethinyl Estradiol Tablets, USP, 0.09 mg/0.02 mg, the generic equivalent to Pfizer's Lybrel tablets. Watson expects to launch the product shortly. Lybrel® had total U.S. sales of just under $12 million for the twelve months ending April 30, 2011, according to IMS Health. Lybrel® tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.